Institut National De La Sante Et De La Recherche Medicale

Societe Civile Bioprojet

Bioprojet

Other

Bioproject

Societe Civile Bioproject

Université De Caen

Universite De Caen - Esplanade De La Faix

Jean-Michel Arrang

Jean-Charles Schwartz

Jeanne-Marie Lecomte

Monique Garbarg

Walter Schunack

Holger Stark

Xavier Ligneau

Charon R Ganellin

Ralph Lipp

Katja Purand

Sigurd Elz

Fabien Leurquin

Antonio Guglietta

Manuel M Raga

Juan Sallares

Marta Guerrero

Abdellatif Fkyerat

Wasyl Tertiuk

Charon Ganellin

Max-Fernand Robba

Jean-Charles M Lancelot

Hulger Stark

Agnes Quemener

Walter G Schunack

Annette Huls

Reidemeister Sybille

Athmani Salah

Nadia Pelloux-Leon

Charon Robbin Ganellin

Wasyl Tertiux

Sadek Bassem

Michael C O Krause

Jeanne-Marie Lecounte

Walter G Schunacx

Monigue Garborg

A method is provided for the treatment of sleep apnea and other conditions wherein an effective amount of crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride of formula (I): optionally comprising water up to 6%, and having an X-ray diffractogram that comprises characteristic peaks (2&#x3b8;) at 11.2&#xb0;, 19.9&#xb0;, 20.7&#xb0; and 34.1&#xb0;&#xb1;0.2&#xb0; is administered to a patient in need thereof.

Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine

The invention relates to new crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride, the respective manufacture and methods of use, and compositions containing such a compound.

Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine

Use of a compound of formula (A), wherein: W is a residue which imparts antagonistic and/or agonistic activity at histamine H-receptors when attached to an imidazole ring in 4(5) position; Rand Rmay be identical or different and represent each independently a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are attached, a saturated nitrogen-containing ring (i) as defined, a non-aromatic unsaturated nitrogen-containing ring (ii) as defined, a morpholino group, or a N-substituted piperazino group as defined for preparing medicaments acting as antagonists and/or agonists at the H-receptors of histamine.

[object Object]

Use of a compound of formula (A), wherein: W is a residue which imparts antagonistic and/or agonistic activity at histamine H-receptors when attached to an imidazole ring in 4(5) position; Rand Rmay be identical or different and represent each independently a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are attached, a saturated nitrogen-containing ring (i) as defined, a non-aromatic unsaturated nitrogen-containing ring (ii) as defined, a morpholino group, or a N-substituted piperazino group as defined for preparing medicaments acting as antagonists and/or agonists at the H-receptors of histamine 

Novel imidazole derivatives as histamine receptor H,antagonists and/or agonists, preparation thereof and therapeutical uses thereof. Chemical compounds for use as histamine receptor H,agonists, partial agonists or antagonists, having general formula (Ia) or (Ib), the use thereof for making drugs, and methods for revealing the agonist, partial agonist or antagonist activity of such compounds in vivo, are disclosed.

Imidazole derivatives as histamine receptor H3 (ANT) agonists

A compound selected from the group consisting of a compound of the formula ##STR1## having antagonist properties to histamine H.sub.3 -receptors.

Imidazole derivatives for pharmaceutical use

Imidazole compounds and their therapeutic applications

Azomethines agonist compounds of the histamine H.sub.3 receptor for

The compounds correspond to the general formula ##STR1## in which R.sub.1 represents a hydrogen atom or a group --COR.sub.2, in which R.sub.2 represents a benzene ring, cyclopentylmethyl, cyclohexylmethyl, cyclopentylethyl or cyclohexylethyl groups or cyclopentylamine, cyclohexylamine or phenylamine, chlorophenylamine or dichlorophenylamine groups; R represents a hydrogen atom or a group COR.sub.3, in which R.sub.3 represents an aliphatic group, a cyclane or benzene ring-system, a group a group (CH.sub.2).sup.m R.sub.4, a group --CH.dbd.CHR.sub.8 or a secondary amine group --NH(CH.sub.2).sub.n R.sub.g ; R also represents a hydroxyalkenyl group: ##STR2##

4-(4-imidazolyl) piperidines substituted at position 1, their

The present invention relates to .alpha.,.beta.-dimethylhistamine, of the rmula: ##STR1## in racemic form, or an optical isomer form or mixture of diastereoisomers and its acid addition salts. It may be prepared from an alkyl 2-amino 3-(1H-imidazol-4-yl)-carboxylate.

Histamine derivative, process for preparing it and its therapeutic use

The invention relates to a pharmaceutical composition containing histamine derivatives and to a method for treating diseases which involve histamine release and synthesis in the human or animal body.

Pharmaceutical compositions and methods for stimulating H.sub.3

Compounds of general formula ##STR1## in which R.sub.1 denotes H, CH.sub.3 or C.sub.2 H.sub.5, R denotes H or R.sub.2 and R.sub.2 denotes an alkyl, piperonyl, 3-(1-benzimidazolonyl)-propyl group; a group of formula ##STR2## in which n is 0, 1, 2, or 3, X is a single bond or alternatively --O--, --S--, --NH--, --CO--, --CH.dbd.CH-- or ##STR3## and R.sub.3 is H, CH.sub.3, F, CN or an acyl group; or alternatively a group of formula ##STR4## in which Z denotes an O or S atom or a divalent group NH, N --CH.sub.3 or N --CN, and R.sub.5 denotes an alkyl group, a cycloalkyl group which can bear a phenyl substituent, a phenyl group which can bear a CH.sub.3 or F substituent, a phenylalkyl(1-3 C) group or a naphthyl, adamantyl or p-toluenesulphonyl group. These compounds are useful to control the release of cerebral histamine and to increase the rate of renewal of cerebral histamine.

(4-imidazolyl)piperidines, the preparation thereof and their application

Growing community of inventors

Dourdan, France

Jean-Michel Arrang